Ovarian Epithelial-stromal Interactions: Role of Interleukins 1 and 6

Overview

Journal Obstet Gynecol Int

Publisher Wiley

Specialty Gynecology & Obstetrics

Date 2011 Jul 19

PMID 21765834

Citations 4

Authors

Kamisha T Woolery

Patricia A Kruk

Affiliations

Soon will be listed here.

Abstract

Ovarian epithelial cancer is the most lethal gynecologic malignancy. The high mortality is attributed to the fact that most cases typically present in late stage when ovarian cancer (OC) has already spread beyond the ovary. Ovarian epithelial cancer cells are shed into intraperitoneal ascites and easily disseminate throughout the peritoneal cavity with preferential metastasis to the omentum, peritoneum, and local organs. Understanding how ovarian epithelial cells interact with and modulate their microenvironment can provide insight into the molecular mechanism(s) involved with malignant transformation and progression which may eventually identify novel diagnostic, prognostic, and therapeutic targets. The objective of this paper is to provide a brief consideration of ovarian surface epithelial-stromal interactions in regard to normal physiological function and tumor progression as influenced by two potentially key interleukins, interleukins-1 (IL-1) and -6 (IL-6), present in the microenvironment. Lastly, we will consider the clinical implications of IL-1 and IL-6 for OC patients.

Citing Articles

Beneficial Effects of Traditional Chinese Medicine in the Treatment of Premature Ovarian Failure.

Li M, Xiao Y, Wei L, Liu Q, Liu P, Yao J Evid Based Complement Alternat Med. 2022; 2022:5413504.

PMID: 36471694 PMC: 9719426. DOI: 10.1155/2022/5413504.

Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions.

Chudecka-Glaz A, Cymbaluk-Ploska A, Menkiszak J, Pius-Sadowska E, Machalinski B, Sompolska-Rzechula A Onco Targets Ther. 2015; 8:471-85.

PMID: 25750541 PMC: 4348053. DOI: 10.2147/OTT.S73438.

Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.

Ataie-Kachoie P, Morris D, Pourgholami M PLoS One. 2013; 8(4):e60817.

PMID: 23593315 PMC: 3620477. DOI: 10.1371/journal.pone.0060817.

Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Kipps E, Tan D, Kaye S Nat Rev Cancer. 2013; 13(4):273-82.

PMID: 23426401 PMC: 4673904. DOI: 10.1038/nrc3432.

References

Percy C, Muir C . The international comparability of cancer mortality data. Results of an international death certificate study. Am J Epidemiol. 1989; 129(5):934-46. DOI: 10.1093/oxfordjournals.aje.a115226. View

Jarboe E, Folkins A, Drapkin R, Ince T, Agoston E, Crum C . Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 2008; 53(2):127-38. DOI: 10.1111/j.1365-2559.2007.02938.x. View

Kaufmann M, von Minckwitz G . Gemcitabine in ovarian cancer: an overview of safety and efficacy. Eur J Cancer. 1997; 33 Suppl 1:S31-3. DOI: 10.1016/s0959-8049(96)00338-3. View

Vergara D, Merlot B, Lucot J, Collinet P, Vinatier D, Fournier I . Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2009; 291(1):59-66. DOI: 10.1016/j.canlet.2009.09.017. View

Shan W, Liu J . Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009; 8(19):3107-11. DOI: 10.4161/cc.8.19.9590. View

Theriault B, Shepherd T, Mujoomdar M, Nachtigal M . BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis. 2007; 28(6):1153-62. DOI: 10.1093/carcin/bgm015. View

Stadlmann S, Amberger A, Pollheimer J, Gastl G, Offner F, Margreiter R . Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol. 2005; 97(3):784-9. DOI: 10.1016/j.ygyno.2005.02.017. View

Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I . Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol. 2009; 14(5):383-91. DOI: 10.1007/s10147-009-0935-y. View

Elloul S, Vaksman O, Stavnes H, Trope C, Davidson B, Reich R . Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis. 2010; 27(3):161-72. DOI: 10.1007/s10585-010-9315-2. View

10.

Vessey M, Jones L . The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age. Br J Obstet Gynaecol. 1989; 96(7):783-8. DOI: 10.1111/j.1471-0528.1989.tb03316.x. View

11.

GONDOS B . Surface epithelium of the developing ovary. Possible correlation with ovarian neoplasia. Am J Pathol. 1975; 81(2):303-21. PMC: 2032215. View

12.

Bookman M, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs J . Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998; 16(10):3345-52. DOI: 10.1200/JCO.1998.16.10.3345. View

13.

Gorospe W, Spangelo B . Interleukin-6 production by rat granulosa cells in vitro: effects of cytokines, follicle-stimulating hormone, and cyclic 3',5'-adenosine monophosphate. Biol Reprod. 1993; 48(3):538-43. DOI: 10.1095/biolreprod48.3.538. View

14.

Collino F, Revelli A, Massobrio M, Katsaros D, Schmitt-Ney M, Camussi G . Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population. Exp Cell Res. 2009; 315(17):2982-94. DOI: 10.1016/j.yexcr.2009.06.010. View

15.

Creemers G, Bolis G, Gore M, Scarfone G, Lacave A, Guastalla J . Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol. 1996; 14(12):3056-61. DOI: 10.1200/JCO.1996.14.12.3056. View

16.

Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M . Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res. 1999; 59(5):1029-35. View

17.

Mustea A, Pirvulescu C, Konsgen D, Braicu E, Yuan S, Sun P . Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine. 2008; 42(1):77-84. DOI: 10.1016/j.cyto.2008.01.011. View

18.

McSorley M, Alberg A, Allen D, Allen N, Brinton L, Dorgan J . C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007; 109(4):933-41. DOI: 10.1097/01.AOG.0000257126.68803.03. View

19.

Arend W, Palmer G, Gabay C . IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008; 223:20-38. DOI: 10.1111/j.1600-065X.2008.00624.x. View

20.

Carmi Y, Voronov E, Dotan S, Lahat N, Rahat M, Fogel M . The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol. 2009; 183(7):4705-14. DOI: 10.4049/jimmunol.0901511. View